HLA-DRB11301和1302可预防慢性乙型肝炎。

HLA-DRB11301 and 1302 protect against chronic hepatitis B.

作者信息

Höhler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, Protzer U, Löhr H F, Schneider P M, Meyer zum Büschenfelde K H, Rittner C

机构信息

I. Department of Internal Medicine, Johannes Gutenberg University Mainz, Germany.

出版信息

J Hepatol. 1997 Mar;26(3):503-7. doi: 10.1016/s0168-8278(97)80414-x.

DOI:10.1016/s0168-8278(97)80414-x

PMID:9075656

Abstract

BACKGROUND/AIMS: The outcome of acute hepatitis B infection may be influenced by host factors like the major histocompatibility complex (MHC). We have investigated MHC class I and class II antigens in patients with chronic hepatitis B compared to a healthy control population. To confirm the findings of this first study we performed a second study in a group of subjects who had spontaneously recovered from acute hepatitis B infection.

METHODS

Frequencies of MHC class I and class II antigens were analyzed in patients with chronic hepatitis B virus infection and in control subjects. MHC class I typing was done by standard microlymphocytotoxicity assays. DRB1 and DQA1 genotypes were determined by polymerase chain reaction based typing methods.

RESULTS

In the first study the class II allele HLA-DRB11301-02 was found in 4 of 70 subjects with chronic hepatitis B virus infection (5.7%) compared to 27 of 101 healthy controls (26.7%, relative risk 0.17; p=0.001; p(corr)=0.025). This protective effect of the DRB11301-02 allele was confirmed in the second study. Eight of 24 patients (33.3%) who cleared hepatitis B virus spontaneously were positive for DRB1*1301-02 (relative risk of developing chronic infection compared to chronic hepatitis B subjects 0.12; p=0.004). Subtyping confirmed that 1301 and 1302 were both decreased in frequency in patients with chronic hepatitis B.

CONCLUSIONS

The MHC class II allele DRB1* 1301-02 is associated with protection from chronic hepatitis B in Caucasian patients.

摘要

背景/目的：急性乙型肝炎感染的转归可能受宿主因素如主要组织相容性复合体（MHC）的影响。我们比较了慢性乙型肝炎患者与健康对照人群的MHCⅠ类和Ⅱ类抗原。为证实第一项研究的结果，我们对一组从急性乙型肝炎感染中自发康复的受试者进行了第二项研究。

方法

分析慢性乙型肝炎病毒感染患者和对照受试者中MHCⅠ类和Ⅱ类抗原的频率。MHCⅠ类分型通过标准的微量淋巴细胞毒试验进行。DRB1和DQA1基因型通过基于聚合酶链反应的分型方法确定。

结果

在第一项研究中，70例慢性乙型肝炎病毒感染受试者中有4例（5.7%）发现Ⅱ类等位基因HLA-DRB11301-02，而101例健康对照中有27例（26.7%）（相对风险0.17；p=0.001；p（校正）=0.025）。第二项研究证实了DRB11301-02等位基因的这种保护作用。24例自发清除乙型肝炎病毒的患者中有8例（33.3%）DRB1*1301-02呈阳性（与慢性乙型肝炎受试者相比发生慢性感染的相对风险为0.12；p=0.004）。亚型分析证实慢性乙型肝炎患者中1301和1302的频率均降低。